JAZZ PATAGONIA (Parkinson’s Disease) This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson’s disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD […]
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
CogMS – A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis The present study will investigate the correlation between objective and subjective cognition in multiple sclerosis. The study will also investigate the impact of covariates such as fatigue and depression, the relationship with the Expanded Disability Status Scale (EDSS) and brain volumetrics as
ENVISION Trial The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer’s disease. What is Alzheimer’s Disease? Alzheimer’s is
PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is being studied to see if it can slow the progression of Parkinson’s disease. It is designed to block a
Testing the hypothesis that treatment with NRX-101 is superior to standard of care (lurasidone) in improving symptoms of depression as measured by the total Montgomery Åsberg Depression Rating Scale (MADRS-10) score in patients with bipolar depression and subacute suicidal ideation and behavior (SSIB) which does not require hospitalization.
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Meniere’s Study Have you been diagnosed with Meniere’s Disease? Do you frequently experience vertigo? If you answered yes to these questions and are over the age of 18, you may qualify for a research study. Qualified participants will receive at no cost: All study-related exams Study drug or placebo (no active ingredient) If you are
A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.
